The Quotes are Powered By Forexpros, the Forex, Futures, and Stock Markets Portal.




A new report show how the drug Tamiflu was a heavy hoax from the pharmaceutical industry

Thursday, 21 March 2013
"Sweden and several other countries were deceived by the pharmaceutical company Roche to purchase large quantities of influenza medicine, Tamiflu". This is the verdict of some specialists whom after examining the drug, feel that it was a very chap drug sold a wonder drug.

According to Swedish television news report about the exposure of what it describe as "the biggest robbery in the history of Europe," the medicine is said to be "no better than ordinary fever pills," one of the world's strongest research reviewers said.

"European governments have been lured into wasting billions of taxpayers' money on something that we do not know is better than an aspirin. I think this is theft," said medical professor, Peter C. Gotzsche to Swedish television when he was contacted in Rigshospitalet in Copenhagen.

"I consider Tamiflu purchases as the largest theft in the history of Europe," he continues.

Peter C. Gotzsche, head of the Nordic part of the world's renowned research organisation  Cochrane Institute, an independent organization which with the help of grants from governments, universities and individuals, review medical research and evaluate different treatments.

Cochran Institute has in several studies questioned the effectiveness of the flu medicine Tamiflu and Peter C. Gotzsche told Swedish television that he doubts if the drug is better than ordinary fever pills, such as Alvedon and Panadol.

Tamiflu is sold in tablet form and is not a vaccine. The manufacturer Roche has marketed the medicine on ground that its properties can prevent people from being infected in a flu pandemic and reduce the risk of serious complications of flu, such as pneumonia.
Since 2011 after the out break of the H1N1 virus in 2009, Tamiflu was considered as one of the world's most important medicines by the World Health Organization.

But researchers of the Cochran's institute who have tested the drug continue to question its effectiveness and wonder why Roche has not been able to defend their support for it through publishing studies carried out to show that medication works.

The Swedish Drug Administration which approved Tamiflu say they are satisfied with the information they received from Roche - and that Cochran Institute's criticism does not affect their assessment of Tamiflu.

But it is not enough for Peter C Gøtzsche and colleagues. Cochran Institute want to have access to all the studies done on Roche's Tamiflu, and have received great support for their demands from a variety of other heavy partners in medical research, including journal British Medical Journal who campaigns on the subject.
by Team

Print Friendly and PDF